Tango Therapeutics Inc TNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $31.56
- Day Range
- $29.45–31.63
- 52-Week Range
- $4.13–32.66
- Bid/Ask
- $29.55 / $29.62
- Shares Outstanding
- 144.65M
- Market Cap
- $4.30B
- Volume/Avg
- 4M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 68.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 137
- Website
- https://www.tangotx.com
Valuation
|
Metric
|
TNGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.62 |
Price/Sales | 68.91 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TNGX
|
|---|---|
Quick Ratio | 26.51 |
Current Ratio | 27.38 |
Interest Coverage | — |
Quick Ratio
TNGX
Profitability
|
Metric
|
TNGX
|
|---|---|
Return on Assets (Normalized) | −24.82% |
Return on Equity (Normalized) | −32.21% |
Return on Invested Capital (Normalized) | −30.40% |
Return on Assets
TNGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Swldlhbck | Zgghmzx | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rjvxyvvnq | Zlcwbk | $65B | |||
| argenx SE ADR
ARGX
| Yqjnwjxlx | Qhk | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vvdnbsjr | Grcppdm | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Vgphvdvnl | Mjscslf | $25B | |||
| BioNTech SE ADR
BNTX
| Cpqllfs | Kwc | $22B | |||
| Incyte Corp
INCY
| Sgyzfqbn | Vrmqj | $21B | |||
| Moderna Inc
MRNA
| Skrjyrjm | Dvwq | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bxcnfglzg | Tryt | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ppttgxxk | Bhvq | $13B |
United States